OR WAIT 15 SECS
Clinicians now have a tool to rapidly assess the efficacy of enoxaparin (Lovenox, Aventis) at the point-of-care. PharmaNetics, Morrisville, NC, recently launched the ENOX test card, which is used to detect the anticoagulant effects of enoxaparin, which is approved for seven indications, including the prophylaxis of ischemic complications of unstable angina and non-Q wave myocardial infarction. Enoxaparin is approved for more clinical indications than any other low-molecular weight heparin. PharmaNetics plans to launch its product during the first quarter of 2003.
Related Content:Treatment Areas